Prestige Consumer Healthcare (NYSE:PBH) Announces Quarterly Earnings Results

Prestige Consumer Healthcare (NYSE:PBH) issued its earnings results on Thursday. The company reported $1.14 earnings per share for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02), FiscalAI reports. Prestige Consumer Healthcare had a net margin of 18.09% and a return on equity of 12.43%. The firm had revenue of $283.44 million for the quarter, compared to the consensus estimate of $286.93 million. During the same period last year, the firm earned $1.22 earnings per share. The company’s revenue for the quarter was down 2.4% on a year-over-year basis. Prestige Consumer Healthcare updated its FY 2026 guidance to 4.540-4.540 EPS.

Here are the key takeaways from Prestige Consumer Healthcare’s conference call:

• Clear Eyes supply is improving sequentially and management expects further progress in Q4 and through calendar 2026 after acquiring Pillar Five and installing a new high-speed line, which should enable internal production, SKU expansion and renewed marketing support.
• Q3 revenue of $283.4 million declined ~2.4% YoY (2.2% ex-FX) and adjusted EPS slipped to $1.14, driven primarily by Clear Eyes supply constraints and category softness in analgesics and cough & cold.
• Strong cash generation (YTD free cash flow of $208.8 million, +12.9%) underpins disciplined capital allocation: the company closed the ~$110 million Pillar Five deal and repurchased >$150 million of shares (~5% of outstanding), while maintaining net debt of ~$1 billion (leverage ~2.6x).
• Management narrowed fiscal 2026 guidance to about $1.1 billion in revenue and ~$4.54 adjusted EPS, expects Q4 adjusted gross margin ~57%, A&M just under 14% of sales and full-year G&A just over 10%, and will provide more 2027 detail on the May call.

Prestige Consumer Healthcare Stock Down 2.2%

Shares of NYSE PBH traded down $1.45 during trading hours on Thursday, hitting $65.58. 528,495 shares of the stock were exchanged, compared to its average volume of 378,281. Prestige Consumer Healthcare has a 12 month low of $57.25 and a 12 month high of $90.04. The firm has a fifty day moving average price of $62.94 and a 200-day moving average price of $64.12. The company has a quick ratio of 2.51, a current ratio of 3.70 and a debt-to-equity ratio of 0.55. The company has a market cap of $3.15 billion, a PE ratio of 16.27, a PEG ratio of 2.02 and a beta of 0.43.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 719 shares of Prestige Consumer Healthcare stock in a transaction on Friday, November 28th. The shares were sold at an average price of $60.00, for a total value of $43,140.00. Following the transaction, the vice president directly owned 42,329 shares of the company’s stock, valued at approximately $2,539,740. The trade was a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.40% of the company’s stock.

Institutional Trading of Prestige Consumer Healthcare

Several large investors have recently added to or reduced their stakes in the company. CIBC Private Wealth Group LLC boosted its stake in shares of Prestige Consumer Healthcare by 142.8% in the third quarter. CIBC Private Wealth Group LLC now owns 1,100 shares of the company’s stock worth $69,000 after buying an additional 647 shares during the last quarter. CIBC Bancorp USA Inc. acquired a new position in Prestige Consumer Healthcare in the third quarter valued at approximately $329,000. Danske Bank A S purchased a new stake in Prestige Consumer Healthcare in the 3rd quarter worth approximately $37,000. Advisory Services Network LLC acquired a new stake in shares of Prestige Consumer Healthcare during the 3rd quarter worth approximately $181,000. Finally, Morningstar Investment Management LLC purchased a new position in shares of Prestige Consumer Healthcare during the 3rd quarter valued at approximately $956,000. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on PBH. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Oppenheimer reduced their price target on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a report on Tuesday, October 21st. Zacks Research upgraded shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, November 10th. Canaccord Genuity Group cut their price objective on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Finally, Jefferies Financial Group reduced their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research note on Friday, January 30th. Four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $84.50.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).